Qulipta is a prescription medication used for the preventive treatment of migraine in adults [1]. It belongs to a class of drugs known as calcitonin gene-related peptide (CGRP) receptor antagonists [1].
How does Qulipta work to prevent migraines?
Qulipta works by blocking the action of CGRP, a molecule that is believed to play a role in migraine pain [1]. By inhibiting CGRP from binding to its receptor, Qulipta helps to reduce the frequency of migraine attacks [1].
Who manufactures Qulipta and when did it become available?
Qulipta is manufactured by AbbVie Inc. [1]. It was approved by the U.S. Food and Drug Administration (FDA) in September 2021 [1].
What is the typical dosage and administration of Qulipta?
Qulipta is available in two strengths: 10 mg and 60 mg, taken orally once daily [1]. The recommended starting dose is 10 mg once daily, and the dose can be increased to 60 mg once daily if needed [1].
What are the potential side effects of Qulipta?
Common side effects associated with Qulipta include nausea, constipation, and indigestion [1]. Less common side effects may also occur [1].
What is the patent status and potential for generic competition for Qulipta?
Information regarding Qulipta's specific patent expiration dates and the timeline for potential generic entry can be found through resources like DrugPatentWatch.com [2]. Pharmaceutical patents typically provide market exclusivity for a certain period, after which generic versions may become available [2].